Are retail investors acquiring Genprex (USA Stocks:GNPX) or SEI Investments?
 | By Gabriel Shpitalnik | Macroaxis Story |
By comparing the basic indicators of Genprex and SEI, you can examine the impact of market volatility on their prices and assess their potential to mitigate market risk when combined in a portfolio. Pair trading strategies, such as matching a long position in SEI with a short position in Genprex, can also be employed. For more details, refer to our pair correlation module.
Now, let's consider Genprex's assets. Asset utilization is a measure of the profit generated for each dollar of reported assets. Genprex has a negative asset utilization rate of -0.85 percent, implying a loss of $0.008497 for each dollar of assets held. This suggests that the company is not effectively using its resources, which is a cause for concern.
Key Takeaways
Despite Genprex's challenging financial position, with a net income showing a loss of 31.5M and a high probability of bankruptcy at 96.43%, the company's stock has shown resilience with a 52-week high of 46. However, investors should exercise caution given the company's negative Z score of -9.01, indicating potential financial distress.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
In the world of biotechnology, the only constant is change. Genprex, a player in the healthcare industry, is no exception. As of March 30, 2024, the company has been experiencing a significant momentum, but the question remains: will this trend continue to accelerate? With a market capitalization of just $5.7M, Genprex is a small-cap company with a relatively low price to book ratio of 0.46X. This suggests that the market may be undervaluing the company's assets, which total $25.09M. However, it's important to note that Genprex's net income shows a loss of $31.5M, which has led to a negative return on equity of -1.58. The company's debt to equity ratio stands at a minimal 1.11%, indicating a conservative approach to leveraging. However, the high probability of bankruptcy at 96.43% cannot be overlooked. Despite these challenges, Genprex has managed to maintain a positive working capital of $18.66M, indicating its ability to meet short-term obligations. The company's 50-day moving average is $5.287, showing a steady upward trend. In conclusion, while Genprex's momentum is currently on the rise, investors should keep a close eye on the company's financial health and market conditions. The biotechnology industry is known for its volatility, and only time will tell if Genprex can maintain its current trajectory. Many prudent traders are steering clear of the biotechnology sector, making it worthwhile to delve deeper into Genprex and compare it with similar entities like SEI Investments. We will examine some competitive aspects of both Genprex and SEI.Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in Genprex. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its performance over time. Several factors influence the investment perspective on Genprex, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring Genprex on a daily basis if you are holding a position in it. Genprex is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Genprex stock to be traded above the $1 level to remain listed. If Genprex stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Genprex's Liquidity
Genprex financial leverage refers to using borrowed capital as a funding source to finance Genprex ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Genprex financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Genprex's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Genprex's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Genprex's total debt and its cash.
Genprex Gross Profit
Genprex Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Genprex previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Genprex Gross Profit growth over the last 10 years. Please check Genprex's gross profit and other fundamental indicators for more details.
Going after Genprex Financials
As the saying goes, past performance is not indicative of future results. Genprex, a clinical-stage gene therapy company, has shown a considerable momentum in the past, but there are concerns about its future performance. The company has a high probability of bankruptcy at 96.43%, a negative beta of -0.57 indicating potential instability, and significant operating losses of $31.7M. However, it has a strong current ratio of 10.71X, indicating good short-term financial health. Given these factors, while Genprex's past momentum has been impressive, investors should proceed with caution due to the company's high-risk profile.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Genprex. Please refer to our Terms of Use for any information regarding our disclosure principles.